Mr. Wu Zhiyuan, Director of the Development Research Center of the People's Government of Pudong New Area, and his entourage visited Mabwell Bioscience for research and guidance on October 20, in order to fulfill the requirements of extensive visit and investigation to "prevent epidemics, stabilize economy and ensure safety", further promote the concentrated development of the biomedical industry, accelerate the innovation of MAH system and enhance the competitiveness of the whole industrial chain. They visited the company on the spot, listened to the company's introduction, and held discussion and exchange with the company leader. Dr. Liu Datao, co-founder and CEO of Mabwell, accompanied the research.

During the discussion, Dr. Liu Datao first introduced in detail the layout of the whole industrial chain of Mabwell since its establishment, focusing on the source innovation and independent innovation capabilities, and the progress of development of key products of the company. After listening to the report, Director Wu Zhiyuan fully affirmed the steady development of Mabwell. Both sides discussed the positive effects of MAH system in promoting the flexible flow of various elements of the pharmaceutical market, stimulating R&D enthusiasm, protecting the rights and interests of innovators, optimizing resource integration, and accelerating the marketing of innovative drugs. Director Wu Zhiyuan encouraged pharmaceutical companies to actively innovate, resonate with the construction of Pudong New Area, and assist in the long-term development of the pharmaceutical industry.

Subsequently, Director Wu Zhiyuan and his entourage visited Mabwell's Innovation and R&D Center. The head of the Innovation and R&D Center introduced Mabwell's advantages of Innovation and R&D and advanced R&D platform facilities. Relying on the high-efficiency innovative platform for drug molecule discovery, Mabwell has two "first-in-China" products in clinical trials and one "first-in-the-world" product whose application for clinical trial has been accepted by NMPA, and all these products are under application for marketing in both China and the United States. At present, the company has a total of 1 product on the market, 2 products in NDA and 3 products in pivotal clinical trial stage. In the future, the company will continue to innovate, and bring more high-quality and highly accessible biopharmaceuticals to the market by virtue of the advantages of the whole industrial chain, so as to meet the clinical needs of more patients.